MOLCURE Inc. (Exited)
Designing highly functional antibodies for diseases without effective treatment
MOLCURE combines Next Generation Sequencing (NGS), bioinformatics and antibody engineering to develop a highly functional discovery platform Abtracer™. Abtracer™ eliminates inherent bias of conventional methods and creates highly functional antibodies for pharmaceutical development.
Ryu Ogawa, the founder of Molcure, was striving to become a scientist at Keio University when he lost his father to cancer. This motivated him to establish a startup that enables the shortest path to cancer drug discovery and development.
By combining conventional methods for antibody production with a next-generation sequencer and Machine Learning, Molcure has developed a drug discovery platform that enables the acquisition of high-performance antibodies that could not be detected by existing methods.
UTEC’s value add
UTEC provides multifaceted support in the form of funding, introducing collaborators, designing business strategies, and introducing customers.
Proprietary antibody development platform : Abtracer.